Myelosuppression is one of the most common and severe adverse events associated with anti-14 cancer therapies and can be a source of drug attrition. Current mathematical modeling methods 15 for assessing cytopenia risk rely on indirect measurements of drug effects and primarily focus 16 on single lineage responses to drugs. However, anti-cancer therapies have diverse mechanisms 17 with varying degrees of effect across hematopoietic lineages. To improve predictive 18 understanding of drug-induced myelosuppression, we developed a quantitative systems 19 pharmacology (QSP) model of hematopoiesis in vitro for quantifying the effects of anti-cancer 20 agents on multiple hematopoietic cell lineages. We calibrated the system parameters of the 21 model to cell kinetics data without treatment and then validated the model by showing that the 22 inferred mechanisms of anti-proliferation and/or cell-killing are consistent with the published 23 mechanisms for three classes of drugs with different mechanisms of action. Using a set of 24 compounds as a sample set, we then analyzed novel compounds to predict their mechanisms 25 and magnitude of myelosuppression. Further, these quantitative mechanisms are valuable for 26 the development of translational in vivo models to predict clinical cytopenia effects. 27 28 Author Summary 29 Reduced bone marrow activity and levels of mature blood cells is an undesirable side effect of 30 many anti-cancer therapies. Selecting promising lead compounds for further development 39 40
31
requires understanding of potential myelosuppressive effects. However, existing preclinical 32 experiments and modeling formulations fail to consider drug effects on multiple blood cell types 33 or the mechanistic differences between how drugs induced myelosuppression. Here we 34 developed a quantitative systems pharmacology (QSP) model that estimates a drug candidate's 35 effect on multiple precursor and mature blood cell lineages and further distinguishes how the 36 drug affects these populations -through cell-killing or anti-proliferation mechanisms. This 37 modeling formalism is valuable for vetting compounds for therapeutic development and for 38 further translational modeling to anticipate the clinical effects of compounds. Introduction
42
Drug-induced myelosuppression is one of the most severe adverse events (AEs) 43 associated with anti-cancer therapies(1). Myelosupression increases patient fatigue and hinders 44 their daily routines(2,3), and increases patient risk for infection (4). Understanding patient 45 propensity for AEs is required for clinical optimization of both drug selection and dose 46 schedules. Often anti-cancer therapies specifically optimize efficacy on the basis of minimizing undesirable myelosuppressive effects (5, 6) . Despite the frequency of myelosuppression 48 following anti-cancer treatment, predicting the severity of this AE remains challenging(1).
49
Computational models and pre-clinical experiments remain the standard for anticipating 50 and understanding potential myelosuppressive effects. Predictive toxicology approaches can 51 expedite early phase clinical trials and reduce the number of patients treated with ineffective 52 doses (7) . A validation study of 20 compounds demonstrated that pre-clinical in vitro 53 measurements of a drug's 90% inhibition concentrations (IC90) of granulocyte-macrophages 54 was a sufficient predictor of the maximum tolerated dose (MTD) in animals and humans(7).
55
Many modeling approaches have captured the effects of novel compounds on single lineages.
56
For instance, the Friberg model describes the in vivo development of neutrophils using multiple 57 transit compartments where drug treatment can affect the self-renewal and proliferation of 58 immature cell types(8). Importantly, these models have supported safety-mitigating strategies in 59 the clinic. Semi-mechanistic modeling combined with clinical data sufficiently captured G-CSF 60 response and neutrophil loss after chemotherapy(9) and identified an optimal blood monitoring 61 schedule during palbociclib treatment(10).
62
An understanding of mechanistic and lineage-specific effects would advance predictive 63 toxicology approaches. Improved understanding of drug-induced myelosuppression requires a 64 systems-level perspective of hematopoiesis and effects on progenitors to better explain 65 downstream effects on blood cells(11). A challenge to mathematical modeling of 66 myelosuppression is understanding lineage effects in the bone marrow, especially when using 67 indirect measurements in peripheral blood (3, 11, 12 ), suggesting in vitro measurements will be 68 essential to this advancement. A cell-based assay that analyzed the relative anti-proliferative 69 effects of multiple chemotherapies found that the extent of anti-proliferation was associated with 70 the severity of myelosuppression(13). These findings further suggest that a mechanistic 71 understanding of drug-induced cytopenias can inform vetting of multiple drug candidates. cytopenic effects and demonstrates the value in using QSP modeling to anticipate potential 106 safety risks in a predictive, and mechanism-driven fashion. for dropping data at day 0 is the apparent difference in kinetics between days 0 and 2 (including 175 a decline in counts for certain cell types, potentially due to the cells coming out of liquid nitrogen 176 and hence not recovering until day 2) as compared to the subsequent time points; day 9 data 177 was only generated for exploratory purposes as replating was done after the day 6 178 measurement, and hence also dropped for the purpose of model fitting. Using the days 2 to 6 179 data, a hybrid optimization approach (genetic algorithm and local search) was performed to infer 180 a parameter set best compatible with the data (please refer to the Methods section for details).
181
Using the set of parameters identified, the model was able to recapitulate the kinetic data well We used the MLTA to capture dose-dependent drug effects (publication forthcoming).
194
The 96 well assay used simultaneous differentiation of human donor CD34+ stem cells into 195 multiple lineages and measured these lineages using flow cytometry. We tested 51 compounds 196 ( Supplemental Table 1 ). This compound set spanned multiple drug classes and contained Table   258 2). Goodness of fit plots and mean squared error across cell types for the sample drug set 259 (highlighted in Figure 4 ) are included in Supplemental Figures 1-8 . In this model, we allowed drugs to have both anti-proliferation as well as cell-killing 261 effects. However, in order to describe both effects with the most parsimonious parametric 262 representation, we have developed the following novel formulation. The underlying assumption 263 is that under treatment with increasing concentrations, drugs will first manifest anti-proliferation 
284
We additionally plotted these results as Emax expressions that illustrate drug effects at 285 increasing concentrations (Figure 7) . Paclitaxel, docetaxel, and dinaciclib have cell-killing 286 mechanisms (Emax effects > 1.0), though, the classic chemotherapies, paclitaxel, and 287 docetaxel have stronger effects at lower concentrations (Figure 7) . For comparison, we plotted 288 the equivalent information using the experimental IC50 values (Figure 5) . As anticipated, the 289 IC50s describe cumulative effects and Emax expressions identify specific cell type effects. In 290 particular, the percent inhibition for palbociclib as shown in Figure 5D indicates plotted; compounds such as the negative control, thalidomide, had no effects above 0.1 and are 361 not shown. 362 363
Discussion Here we presented an approach using a QSP model of in vitro hematopoiesis for 365 learning lineage-specific drug mechanisms of myelosuppression. Our ordinary differential 366 equations model described cell kinetics in the absence of drug treatment, as well as drug effect 367 parameter values Emax and EC50 that explain the observed drug effects on multiple 368 hematopoietic cell types. The major innovation in our approach is the deconvolution and 369 mechanistic interpretation of drug effects on multiple hematopoietic lineages including early 370 progenitors and mature blood cells. By this modeling approach, we were able to estimate the 371 drug effect parameters (Emax and EC50) on each cell type in the hematopoiesis pathway in a 372 manner that is independent of study treatment duration and enables model-based in vitro to in 373 vivo translation that is underway. We expect the model-based translational approach to be 374 more predictive of clinical outcomes, due to the fact that known differences between in vitro and 375 in vivo hematopoiesis are captured in the mathematical models (including proliferation kinetics 376 and feedback mechanisms mediated by cytokines such as G-CSF, EPO and TPO).
377
We used these parameters with multivariate and comparative analyses across Six replicate samples of human donor CD34+ stem cells were seeded in 96 well plates and 432 exposed to a customized cytokine cocktail to promote differentiation (publication forthcoming).
433
Cells were maintained in culture for six days and cell lineages were measured using flow 434 cytometry as described above. 450 451
The 27 system parameters of the model as well as the initial cell counts (at time=0) for each of 452 the 14 cell type modeled were fitted to describe the mean of the kinetic data over the 6 donors.
453
In particular, a hybrid optimization approach combining genetic algorithm with local search was 454 used (as implemented in the Matlab function, ga) to obtain an optimal parameter set that best 455 explain the experimental data. For the algorithm settings, the maximum number of generations 456 (MaxGenerations) and the population size (PopulationSize) were set to 50 and 500 respectively. 498 When developing the model, we considered different formulations: (a) weighting the 499 objective value to prioritize dead cells (b) using a regularization parameter to encourage a 500 parsimonious solution. We assessed the contributions of these formulations using mean-501 squared error and goodness of fit plots for drugs with known mechanisms. We discovered that 502 weighting the distance between the observed and estimated value for the dead cell populations 503 by a factor of two was necessary to fit known cell-killing and anti-proliferation mechanisms.
504
Further, we used a regularization parameter of 0.1 to penalize parameters that were close to 505 zero and ultimately produce a parsimonious set of parameters to explain drug effects. 
